Telix Pharmaceuticals Limited bugun Nyu-Yorkdagi Memorial Sloan Kettering saraton markazida (MSK) kompaniyaning TLX2 (250Lu-DOTA-girentuximab) buyrak saratonini tekshirish bo'yicha "STARLITE 177" II bosqich tadqiqotida birinchi bemorga dozalanganligini e'lon qildi. .
STARLITE 2 (NCT05239533) buyrak saratonining eng keng tarqalgan va agressiv shakli bo'lgan tiniq hujayrali buyrak hujayrali karsinomasi (ccRCC) uchun immunoterapiya bilan birgalikda TLX250 maqsadli nurlanish samaradorligini baholaydi. TLX250 karbonik angidraz IX (CA9) [1] oqsilini maqsad qilib oladi, u saraton immunoterapiyasiga nisbatan cheklangan javobni ko'rsatishi mumkin bo'lgan bemorlarda yuqori darajada ifodalanadi.[2] Kontseptsiya shundan iboratki, maqsadli nurlanishning past dozalari potentsial ravishda immunitet qarshiligini engib o'tishi mumkin - yoki o'simtaning "immuniteti" va shuning uchun uni saraton immunoterapiyasiga ko'proq javob beradi.
Oldingi immunoterapiyadan so'ng o'sgan bemorlarda II bosqich tadqiqoti, Opdivo® [250] (nivolumab) anti-PD-1[3] immunoterapiyasi bilan birgalikda TLX4 tomonidan yuborilgan nurlanishni baholaydi. Asosiy yakuniy nuqta, Telix terapiyasiga javob beradigan o'smalar tomonidan baholangan holda, TLX250 bilan kombinatsiyalangan terapiyaning xavfsizligi va samaradorligini aniqlashdan iborat. CA250 ifodasini tasvirlash uchun tadqiqotda Telix-ning TLX89-CDx (9Zr-DFO-girentuximab) tadqiqot hamkori tasvirlash agenti ham qo'llaniladi. Bir qo'lli tergovchi boshchiligidagi tadqiqot taxminan 30 nafar bemorni qamrab olishi kutilmoqda.
Telix bosh tibbiy direktori, doktor Kolin Xeyvard ta'kidladi: "Aniq yadro tibbiyoti va tibbiy onkologiyaning integratsiyasi davom etmoqda va Telix shaxsiylashtirilgan mahsulotlar va bemorlarga qulay rejimlarni ishlab chiqish bo'yicha ushbu harakatning boshida turibdi. Biz doktor Darren Feldman va uning klinik jamoasiga, shuningdek, ushbu ilg'or tadqiqotga hissa qo'shadigan bemorlarga o'z minnatdorchiligimizni bildirmoqchimiz.
USHBU MAQOLADAN NIMA OLISH KERAK:
- The primary endpoint is to determine the safety and efficacy of combination therapy with TLX250 as assessed by the tumours responding to the Telix therapy versus the current standard of care alone.
- TLX250 targets carbonic anhydrase IX (CA9),[1] a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy.
- STARLITE 2 (NCT05239533) will assess the efficacy of TLX250 targeted radiation in combination with immunotherapy for clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer.
